
Coherus BioSciences (CHRS) Stock Forecast & Price Target
Coherus BioSciences (CHRS) Analyst Ratings
Bulls say
Coherus Oncology is a compelling oncology story because it combines an approved, in-house PD-1 backbone with a differentiated pipeline that can create both near-term cash flow and long-term growth. Loqtorzi generated $14.0M in 3Q26 net product revenue, up 25% YoY, while management said quarterly burn should fall by $6M-$7M over the next two quarters after a ~30% headcount reduction and that $83.6M of cash provides runway through key clinical updates in 2026 and 2027. Fundamentally, the outlook is supported by promising esophageal cancer data for tagmokitug, competitive HCC signals for casdozokitug, and the possibility that pipeline success could expand Loqtorzi beyond NPC into a broader commercial franchise.
Bears say
Coherus Oncology is viewed negatively because its clinical evidence remains preliminary, with the 2L ESCC cohort showing only a 16.7% confirmed ORR at 700 mg, a 33.3% CBR, and no clear proof of PD-1 rescue in the only PD-1-pretreated patient. The bear case assumes casdozokitug and tagmokitug both fail in ESCC, which would leave only NPC Loqtorzi sales of about $240M in FY35, underscoring how much value depends on unproven pipeline assets rather than a broad commercial base. Additional downside comes from regulatory, competitive, and dilution risk, since approvals remain uncertain, rivals are entrenched, and the company may need more capital, with the latest per-share estimate already reflecting only about $9.8M in net cash across roughly 258.4M diluted shares.
This aggregate rating is based on analysts' research of Coherus BioSciences and is not a guaranteed prediction by Public.com or investment advice.
Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction
Start investing in Coherus BioSciences (CHRS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Coherus BioSciences (CHRS) Forecast
Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction
Start investing in Coherus BioSciences (CHRS)
Order type
Buy in
Order amount
Est. shares
0 shares